Membranous Nephropathy Associated with Compounded Tirzepatide: Cause, Cure, or Coincidence (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0736; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Tirzepatide, a dual GIP/GLP-1 agonist approved for type 2 diabetes and obesity, has shown renal benefits in clinical trials...Lisinopril 2.5 mg was initiated, and rituximab therapy was planned...Although causality cannot be confirmed, this case underscores the need for pharmacovigilance distinguishing compounded from branded formulations. GLP-1 agents and their effect on immune function and glomerular disease need to be further studied."
Diabetes • Dyslipidemia • Genetic Disorders • Glomerulonephritis • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus
|
|
Vikas Agrawal; Srinath Yadlapalli; Rebecca J. Ellis; Shunhua Guo; Simit Doshi
|